Kenichi Harada
Overview
Explore the profile of Kenichi Harada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
435
Citations
5292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Hara T, Matsushita Y, Harada K, Fujimoto N, Fujisawa M, Miyake H
Int J Urol
. 2024 Mar;
31(6):696-698.
PMID: 38424707
No abstract available.
32.
Minato A, Murooka K, Okumura Y, Takaba T, Higashijima K, Nagata Y, et al.
In Vivo
. 2024 Feb;
38(2):873-880.
PMID: 38418119
Background/aim: Variant urothelial carcinoma (VUC, defined herein as urothelial carcinoma with any histological variant) is frequently observed at an advanced stage. However, the efficacy of systemic chemotherapy against VUC in...
33.
Minato A, Furubayashi N, Nagata Y, Tomoda T, Masaoka H, Song Y, et al.
Curr Oncol
. 2024 Feb;
31(2):862-871.
PMID: 38392058
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against...
34.
Momtazkari S, Dev Choudhury A, Yong Z, Le D, Nguyen Canh H, Harada K, et al.
J Leukoc Biol
. 2024 Feb;
115(6):1108-1117.
PMID: 38374693
A well-documented Achilles heel of current cancer immunotherapy approaches is T cell exhaustion within solid tumor tissues. The proinflammatory cytokine interleukin (IL)-23 has been utilized to augment chimeric antigen receptor...
35.
Fukuyama Y, Kubo M, Harada K
Prog Chem Org Nat Prod
. 2024 Feb;
123:1-473.
PMID: 38340248
Neurotrophins (NGF, BDNF, NT3, NT4) can decrease cell death, induce differentiation, as well as sustain the structure and function of neurons, which make them promising therapeutic agents for the treatment...
36.
Abuduyimiti T, Goto H, Kimura K, Oshima Y, Tanida R, Kamoshita K, et al.
Am J Pathol
. 2024 Feb;
194(5):693-707.
PMID: 38309428
Glucose lowering independently reduces liver fibrosis in human nonalcoholic fatty liver disease. This study investigated the impact of diabetes on steatohepatitis and established a novel mouse model for diabetic steatohepatitis....
37.
Hara T, Furukawa J, Tsutiya T, Kodama T, Uehara K, Terakawa T, et al.
IJU Case Rep
. 2024 Jan;
7(1):60-63.
PMID: 38173458
Introduction: Renal cell carcinoma with an inferior vena cava tumor thrombus is a challenging disease that requires a multimodal treatment approach. Pembrolizumab plus lenvatinib has displayed promising efficacy in metastatic...
38.
Tobe T, Terakawa T, Ueno Y, Sofue K, Hara T, Furukawa J, et al.
IJU Case Rep
. 2024 Jan;
7(1):30-33.
PMID: 38173447
Introduction: Leiomyosarcoma of the inferior vena cava is associated with poor prognosis. Complete resection is the only curative treatment. We present a patient with this disease in whom cine magnetic...
39.
Calderaro J, Laleh N, Zeng Q, Maille P, Favre L, Pujals A, et al.
Nat Commun
. 2023 Dec;
14(1):8290.
PMID: 38092727
Primary liver cancer arises either from hepatocytic or biliary lineage cells, giving rise to hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICCA). Combined hepatocellular- cholangiocarcinomas (cHCC-CCA) exhibit equivocal or mixed features...
40.
Harada M, Tomisaki I, Shimajiri S, Kuretake K, Harada K, Fujimoto N
IJU Case Rep
. 2023 Nov;
6(6):386-389.
PMID: 37928288
Introduction: Small cell carcinoma (SCC) of the kidney is extremely rare. Although the majority of patients with advanced renal small cell carcinoma were treated with a combination of cisplatin and...